United States · Industrial & Consumer Products · USD (Millions) · Annual
Reported figures and Equlion model projections for the next 5 years.
Sector average
Sector average (own scale)
Amounts in USD (millions); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for ROCKET PHARMACEUTICALS, INC.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | ||||
|---|---|---|---|---|---|---|
| Metric | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
| ROE | -60.27% | -184.68% | 207.78% | 116.13% | 100.05% | 95.84% |
|---|---|---|---|---|---|---|
| Sector average | -229.04% | -10.73% | -40.81% | 47.95% | 47.89% | 72.08% |
| ROA | -52% | -91.26% | -233.24% | -633.87% | - | - |
| Total Assets | $330.45M | $252.89M | $252.89M | $252.89M | $252.89M | $252.89M |
| Sector average | $13,470.79M | $13,845.95M | $15,738.34M | |||
| Net Income | -$223.12M | -$266.18M | -$589.85M | -$1,602.99M | -$4,368.30M | -$12,053.16M |
| $19,113.39M |
| $22,282.55M |
| $24,814.26M |